Clinical trials: Multiple Sclerosis, Primary Progressive
Multiple Sclerosis
Hydroxyurea in Primary Progressive Multiple Sclerosis
The pathogenesis of MS remain elusive, however some studies have linked the disease with infection by Epstein-Barr virus; therefore the use of drugs with immunosuppressive or immunomodulating action alone may be less suitable for…
- Trial name
- NCT01103583
- Testing
- Hydroxyurea
- Where
- 2 sites in Italy
- Volunteers
- 33 people
- Sponsor
- S. Andrea Hospital
Multiple Sclerosis, Progressive Multiple Sclerosis
Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis
This is a three-week crossover study that will compare how the body absorbs and tolerates two different forms of lipoic acid: R form and racemic form.
- Conditions
- Multiple Sclerosis, Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
- Trial name
- NCT03493841
- Testing
- Alpha Lipoic Acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rebecca Spain
Primary Progressive Multiple Sclerosis, Exercise
The Influence of HIIT Versus MCT on Cardiorespiratory Fitness in PPMS
Endurance training revealed to be an effective means to increase cardiorespiratory fitness in persons with Multiple Sclerosis (MS), considered relevant to health-related quality of life in this population.
- Conditions
- Primary Progressive Multiple Sclerosis, Exercise, Cardiorespiratory Fitness
- Trial name
- CYPRO (NCT05229861)
- Testing
- HIIT, MCT
- Where
- Switzerland
- Volunteers
- 61 people
- Sponsor
- Klinik Valens
Multiple Sclerosis
Remote Ischemic Conditioning in PPMS
Progressive MS remains the most difficult therapeutic challenge. Remyelination is a promising therapeutic strategy but an effective pharmacologic intervention remains elusive.
- Trial name
- NCT06171334
- Testing
- Remote ischemic conditioning
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- University of Calgary
Multiple Sclerosis, Progressive
Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis
In this clinical trial, researchers are exploring a novel approach to delivering therapy directly into the spinal fluid, which surrounds and nourishes the brain and spinal cord.
- Trial name
- NCT06841068
- Testing
- Amniotic fluid or placental CD117 stem cells
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Primary Progressive Multiple Sclerosis
Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS
This is a phase IIa study with GA Depot in subjects with Primary Progressive MS. GA Depot will be administered intramuscularly (IM), once every four weeks for 148 weeks.
- Trial name
- NCT03362294
- Testing
- GA Depot 40mg once monthly, GA Depot 25mg once monthly
- Where
- 7 sites in Israel, Moldova
- Volunteers
- 30 people
- Sponsor
- Mapi Pharma Ltd.
Multiple Sclerosis
Assessing the Role of Mitochondrial Dysfunction in Primary Progressive Multiple Sclerosis
The purpose of this project is to study genetic determinants of mitochondrial impairment in primary progressive multiple sclerosis.
- Trial name
- NCT06025903
- Where
- 2 sites in Italy
- Volunteers
- 140 people
- Sponsor
- IRCCS San Raffaele
Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Primary Progressive
The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients
Abstract Introduction: Postural control disorders are the most common motor disorder associated with multiple sclerosis. Objective: The aim of this study is to demonstrate the potential for improvement of postural control, motion…
- Trial name
- NCT03424538
- Testing
- Neurorehabilitation, Physiotherapy
- Where
- Hungary
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Somogy Megyei Kaposi Mór Teaching Hospital
Multiple Sclerosis, Remittent Progressive, Multiple Sclerosis, Primary Progressive
A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
This is a multicenter study conducted in 3 parts. Part A is a double-blind placebo-controlled parallel-group period, and Part B and C are open-label extension periods.
- Conditions
- Multiple Sclerosis, Remittent Progressive, Multiple Sclerosis, Primary Progressive, Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- MOTION - JAPAN (NCT01917019)
- Testing
- BIIB041 (fampridine)
- Where
- 19 sites in Japan
- Volunteers
- 101 people
- Sponsor
- Biogen
Primary Progressive Multiple Sclerosis
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to…
- Trial name
- PERSEUS (NCT04458051)
- Testing
- Tolebrutinib
- Where
- 277 sites in United States, Argentina and 40 more
- Volunteers
- 767 people
- Sponsor
- Sanofi
Multiple Sclerosis
Libyan Multiple Sclerosis Registry Study
This study aims to understand differences in access to diagnosis and treatment for people with multiple sclerosis (MS) receiving care in Libya.
- Trial name
- NCT07264725
- Testing
- Disease-Modifying Therapies
- Where
- Libya
- Volunteers
- 369 people
- Sponsor
- University of Zintan
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS
The purpose of this study is to examine the effect of treatment with fampridine in patients with secondary progressive MS (SPMS) or primary progressive MS (PPMS) with upper limb dysfunction (as defined by a 9-HPT time of between…
- Trial name
- NCT02208050
- Testing
- Fampridine
- Where
- 2 sites in Ireland
- Volunteers
- 64 people
- Sponsor
- University College Dublin
Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
A Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART dose that may be administered safely to patients…
- Conditions
- Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT07085676
- Testing
- HBI0101 CART
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Polina Stepensky
Multiple Sclerosis
Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis
The purpose of this study is to evaluate the activity of oral AB1010, administered at two dose levels during 3 years to patients with primary or secondary progressive multiple sclerosis.
- Trial name
- NCT01450488
- Testing
- masitinib
- Volunteers
- 35 people
- Sponsor
- AB Science
Primary Progressive Multiple Sclerosis
This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.
The purpose of this study is to evaluate whether FTY720 is effective in delaying MS disability progression compared to placebo in patients with PPMS.
- Trial name
- INFORMS (NCT00731692)
- Testing
- FTY720
- Where
- 157 sites in United States, Australia and 16 more
- Volunteers
- 970 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis
Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis
Fatigue is a prevalent symptom in patients with multiple sclerosis (MS) and is associated with considerable impairment in quality of life as well as loss of occupational capacity.
- Conditions
- Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis
- Trial name
- NCT07426991
- Testing
- No Intervention: Observational Cohort
- Where
- 2 sites in Germany
- Volunteers
- 837 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Alzheimer Dementia (AD), ALS - Amyotrophic Lateral Sclerosis
Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders
The goal of this study is to use ultra-high-resolution (UHR) PET imaging to better understand how the brain and spinal cord change in healthy aging and in neurological and psychiatric disorders such as Alzheimer's disease (AD)…
- Conditions
- Alzheimer Dementia (AD), ALS - Amyotrophic Lateral Sclerosis, Parkinson s Disease, REM Sleep Behavior Disorder (iRBD)
- Trial name
- NCT07509125
- Testing
- UHR PET/CT scan of the brain with ¹⁸F-FDG, UHR PET/CT scan of the brain with ¹⁸F-PE2I, UHR PET/CT scan of the brain with ¹⁸F-SynVesT-1
- Where
- Belgium
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Primary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive
Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
The purpose of this study is to compare the efficacy and safety of andrographolide 140 mg administered twice a day orally versus a placebo as a modifying treatment of the disease in patients with the progressive forms of Multiple…
- Trial name
- NCT02273635
- Testing
- Andrographolides
- Where
- Chile
- Volunteers
- 68 people
- Sponsor
- Innobioscience SpA
Primary Progressive Multiple Sclerosis
Gray Matter Demyelination in Primary Progressive MS at 7T
Progressive-onset multiple sclerosis (PPMS) occurs in about 15% of all people living with MS. PPMS remains understudied, and most disease-modifying treatments are ineffective for PPMS.
- Trial name
- NCT04977622
- Where
- Denmark
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Danish Research Centre for Magnetic Resonance
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
ACTH in Progressive Forms of MS
This is a phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and efficacy of adrenocorticotropic hormone (ACTH, Acthar gel) administered as a pulsed regimen consisting…
- Conditions
- Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Trial name
- NCT01950234
- Testing
- ACTH
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of Minnesota